Cargando…

Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma

The lack of sensitive and specific biomarkers hinders pathological diagnosis and prognosis for hepatocellular carcinoma (HCC). Since glutaminolysis plays a crucial role in carcinogenesis and progression, we sought to determine if the expression of kidney-type and liver-type glutaminases (GLS1 and GL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Decai, Shi, Xianbiao, Meng, Gang, Chen, Jun, Yan, Chen, Jiang, Yong, Wei, Jiwu, Ding, Yitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480704/ https://www.ncbi.nlm.nih.gov/pubmed/25844758

Ejemplares similares

Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study
por: Zhang, Laizhu, et al.
Publicado: (2023)

Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway
por: Li, Binghua, et al.
Publicado: (2018)

Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma
por: Ren, L., et al.
Publicado: (2020)

Structure and activation mechanism of the human liver-type glutaminase GLS2
por: Ferreira, Igor M., et al.
Publicado: (2021)

Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation
por: López de la Oliva, Amada R., et al.
Publicado: (2020)

Liver-enriched Genes are Associated with the Prognosis of Patients with Hepatocellular Carcinoma
por: Li, Binghua, et al.
Publicado: (2018)

The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells
por: Wang, Diancheng, et al.
Publicado: (2016)

Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer
por: Lukey, Michael J., et al.
Publicado: (2019)

Author Correction: Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation
por: López de la Oliva, Amada R., et al.
Publicado: (2021)

Mammalian Glutaminase Gls2 Gene Encodes Two Functional Alternative Transcripts by a Surrogate Promoter Usage Mechanism
por: Martín-Rufián, Mercedes, et al.
Publicado: (2012)

GLS2 shapes ferroptosis in hepatocellular carcinoma
por: Suzuki, Sawako, et al.
Publicado: (2023)

The glutaminase (CgGLS-1) mediates anti-bacterial immunity by prompting cytokine synthesis and hemocyte apoptosis in Pacific oyster Crassostrea gigas
por: Liang, Yage, et al.
Publicado: (2021)

Superior anti-tumor efficacy of diisopropylamine dichloroacetate compared with dichloroacetate in a subcutaneous transplantation breast tumor model
por: Su, Lei, et al.
Publicado: (2016)

Inhibition of lncRNA NEAT1 sensitizes medulloblastoma cells to cisplatin through modulating the miR-23a-3p-glutaminase (GLS) axis
por: Ge, Jingjing, et al.
Publicado: (2022)

Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer
por: Saha, Subbroto Kumar, et al.
Publicado: (2019)

Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells
por: Szeliga, Monika, et al.
Publicado: (2013)

Transfection with GLS2 Glutaminase (GAB) Sensitizes Human Glioblastoma Cell Lines to Oxidative Stress by a Common Mechanism Involving Suppression of the PI3K/AKT Pathway
por: Majewska, Ewelina, et al.
Publicado: (2019)

Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma
por: Zhang, Taotao, et al.
Publicado: (2022)

GLS as a diagnostic biomarker in breast cancer: in-silico, in-situ, and in-vitro insights
por: Zhang, Danfeng, et al.
Publicado: (2023)

Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis
por: Qu, Zhen, et al.
Publicado: (2017)

Identification of GLS as a cuproptosis-related diagnosis gene in acute myocardial infarction
por: Liu, Zheng, et al.
Publicado: (2022)

Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma
por: Meng, Gang, et al.
Publicado: (2019)

TMEM147 is a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma
por: Fan, Wen-Jie, et al.
Publicado: (2023)

Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma
por: Yu, Decai, et al.
Publicado: (2007)

SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis
por: Xu, Kangdi, et al.
Publicado: (2022)

Governing glutaminolysis by regulation of glutaminase succinylation
por: Ma, Qingxia, et al.
Publicado: (2021)

The Role of Glutamine and Glutaminase in Pulmonary Hypertension
por: Wang, Shang, et al.
Publicado: (2022)

Regulation of Cardiac Fibroblast GLS1 Expression by Scleraxis
por: Chattopadhyaya, Sikta, et al.
Publicado: (2022)

Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma
por: Meng, Gang, et al.
Publicado: (2019)

Structural basis for exploring the allosteric inhibition of human kidney type glutaminase
por: Ramachandran, Sarath, et al.
Publicado: (2016)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

Nuclear factor-κB p65 regulates glutaminase 1 expression in human hepatocellular carcinoma
por: Dong, Meng, et al.
Publicado: (2018)

Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer
por: Zhang, Junfeng, et al.
Publicado: (2019)

The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy
por: Lukey, Michael J., et al.
Publicado: (2016)

Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer
por: Udupa, Sunag, et al.
Publicado: (2019)

Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome
por: Khoury, Elizabeth Smith, et al.
Publicado: (2020)

Exosome Cargos as Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma
por: Zeng, Yulai, et al.
Publicado: (2023)

Random-forest algorithm based biomarkers in predicting prognosis in the patients with hepatocellular carcinoma
por: Guo, Lingyun, et al.
Publicado: (2020)

Targeting hepatic glutaminase activity to ameliorate hyperglycemia
por: Miller, Russell A., et al.
Publicado: (2018)

Q-ing tumor glutaminase therapy
por: Stine, Zachary E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r4rmcmahp4lchgbalkvjs9k80u